These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18502950)

  • 41. Cost-effectiveness.
    Tuulonen A; Azuara-Blanco A
    Ophthalmology; 2009 Jan; 116(1):166-7; author reply 167. PubMed ID: 19118707
    [No Abstract]   [Full Text] [Related]  

  • 42. Cost-effectiveness.
    Brown GC; Brown MM
    Ophthalmology; 2008 Aug; 115(8):1433; author reply 1433-4. PubMed ID: 18675701
    [No Abstract]   [Full Text] [Related]  

  • 43. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D; Baingana F; Kim J
    J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preferences for 'life-saving' programmes: small for all or gambling for the prize?
    Gyrd-Hansen D; Kristiansen IS
    Health Econ; 2008 Jun; 17(6):709-20. PubMed ID: 17990283
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach.
    Hass B; Lungershausen J; Hertel N; Poulsen Nautrup B; Kotowa W; Liedgens H
    Eur J Health Econ; 2009 Jul; 10(3):309-21. PubMed ID: 19101743
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The cost-effectiveness of hormone therapy in younger and older postmenopausal women.
    Salpeter SR; Buckley NS; Liu H; Salpeter EE
    Am J Med; 2009 Jan; 122(1):42-52.e2. PubMed ID: 19114171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. How should age at diagnosis impact treatment strategy in asymptomatic primary hyperparathyroidism? A cost-effectiveness analysis.
    Zanocco K; Sturgeon C
    Surgery; 2008 Aug; 144(2):290-8. PubMed ID: 18656638
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
    Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
    Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [More recent measures for a nation's state of health--a review].
    Moesgaard Iburg K; Kamper-Jørgensen F
    Ugeskr Laeger; 2003 Jun; 165(26):2637-41. PubMed ID: 12886544
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quality of life--three competing views.
    Sandoe P
    Ethical Theory Moral Pract; 1999; 2(1):11-23. PubMed ID: 15015520
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Measuring health-related quality of life.
    Taylor WJ; McPherson K
    N Z Med J; 1999 Jun; 112(1090):239-40. PubMed ID: 10449001
    [No Abstract]   [Full Text] [Related]  

  • 53. [Analysis of quality of life: quality management or illusion?].
    Determann MM
    Zentralbl Chir; 2008 Feb; 133(1):31-4. PubMed ID: 18278699
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Can we estimate the 'social' value of a QALY? Four core issues to resolve.
    Smith RD; Richardson J
    Health Policy; 2005 Sep; 74(1):77-84. PubMed ID: 16098414
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The importance of quality of survival as an outcome measure for an integrated trauma system.
    Cameron PA; Gabbe BJ; McNeil JJ
    Injury; 2006 Dec; 37(12):1178-84. PubMed ID: 17087962
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Scientific prioritization: inescapable judgement.
    McCulloch D
    Appl Health Econ Health Policy; 2003; 2(2):71-3. PubMed ID: 14619275
    [No Abstract]   [Full Text] [Related]  

  • 57. The value of utility: assumptions underlying preferences and quality adjusted life years.
    Guillemin F
    J Rheumatol; 1999 Sep; 26(9):1861-3. PubMed ID: 10493660
    [No Abstract]   [Full Text] [Related]  

  • 58. Capabilities and health.
    Anand P
    J Med Ethics; 2005 May; 31(5):299-303. PubMed ID: 15863692
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quality-adjusted life-years, comparative effectiveness in cancer care, and measuring outcomes in the underserved.
    Kilbridge KL
    Oncology (Williston Park); 2010 May; 24(6):530-6. PubMed ID: 20568594
    [TBL] [Abstract][Full Text] [Related]  

  • 60. National Institute for Health and Clinical Excellence appraisal and ageism.
    Stevens A; Doyle N; Littlejohns P; Docherty M
    J Med Ethics; 2012 May; 38(5):258-62. PubMed ID: 22213833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.